The historical rank and industry rank for Vaidyane Ayurved Laboratories's Pretax Margin % or its related term are showing as below:
NSE:MADHAVBAUG'
s Pretax Margin % Range Over the Past 10 Years
Min: -0.59 Med: 4.62 Max: 11.01
Current: 10.11
NSE:MADHAVBAUG's Pretax Margin % is ranked better than 58.89% of 956
companies
in the Drug Manufacturers industry
Industry Median: 7.285
vs NSE:MADHAVBAUG: 10.11
The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.
The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.
It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.
The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.
Vaidyane Ayurved Laboratories Pretax Margin % Related Terms
Vaidyane Ayurved Laboratories Pretax Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NSE:MADHAVBAUG vs ZTS, UTHR: Pretax Margin % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Vaidyane Ayurved Laboratories's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vaidyane Ayurved Laboratories Pretax Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Vaidyane Ayurved Laboratories's Pretax Margin % distribution charts can be found below:
* The bar in red indicates where Vaidyane Ayurved Laboratories's Pretax Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Vaidyane Ayurved Laboratories (NSE:MADHAVBAUG) has a Pretax Margin % of 7.62% as of Mar. 2026. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Vaidyane Ayurved Laboratories and its competitors. This is 65% above median its historical median of 4.62. According to the industry distribution chart, Vaidyane Ayurved Laboratories ranks #393 out of 956 companies in the Drug Manufacturers industry, placing it in the top 41.1%.
Is Vaidyane Ayurved Laboratories' Pretax Margin % too high?
Vaidyane Ayurved Laboratories' current Pretax Margin % of 7.62% is 65% above median its 10-year median of 4.62. The Drug Manufacturers industry median Pretax Margin % is 7.29. Vaidyane Ayurved Laboratories' value of 7.62% is 4.6% above this industry median. Based on the distribution chart, Vaidyane Ayurved Laboratories ranks #393 out of 956 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Vaidyane Ayurved Laboratories has a GF Score™ of 82/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Vaidyane Ayurved Laboratories' Pretax Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Vaidyane Ayurved Laboratories ranks #393 out of 956 companies for Pretax Margin %. This puts Vaidyane Ayurved Laboratories in the upper half of its industry. The industry median Pretax Margin % is 7.29. Vaidyane Ayurved Laboratories' value of 7.62% is 4.6% above this benchmark. While the company's 10-year median is 4.62 vs. the industry median of 7.29, Vaidyane Ayurved Laboratories has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Pretax Margin % for a Drug Manufacturers company?
The median Pretax Margin % among Drug Manufacturers companies is 7.29, based on 956 companies in the industry. Companies in the top quartile (top 25%) have a Pretax Margin % significantly above this median, while those in the bottom quartile fall well below. However, Pretax Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Vaidyane Ayurved Laboratories's current Pretax Margin % of 7.62% is 4.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Pretax Margin % mean?
A high Pretax Margin % can signal that a stock is expensive relative to its fundamentals. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Vaidyane Ayurved Laboratories and its competitors. For the Drug Manufacturers industry, the median Pretax Margin % is 7.29 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Vaidyane Ayurved Laboratories's current Pretax Margin % is 7.62%, which is 65% above median its own 10-year median of 4.62. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vaidyane Ayurved Laboratories stock overvalued right now?
Based on GuruFocus' analysis, Vaidyane Ayurved Laboratories (NSE:MADHAVBAUG) is currently considered Modestly Undervalued. The stock's GF Value™ is ₹228.11, compared to a current price of ₹177.00 — trading 22.4% below its estimated fair value. The current Pretax Margin % is 7.62%, which is 65% above median its 10-year median of 4.62 and 4.6% above the Drug Manufacturers industry median of 7.29. Vaidyane Ayurved Laboratories' overall GF Score™ is 82/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Pretax Margin % calculated?
Pretax Margin % is calculated from a company's financial statements. For Vaidyane Ayurved Laboratories (NSE:MADHAVBAUG), the current Pretax Margin % is 7.62% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Vaidyane Ayurved Laboratories (NSE:MADHAVBAUG) Overvalued in 2026?
Based on GuruFocus' analysis, Vaidyane Ayurved Laboratories stock appears to be undervalued.
The current stock price of ₹177.00 is trading 22.4% below its estimated GF Value™ of ₹228.11.
GuruFocus considers Vaidyane Ayurved Laboratories to be Modestly Undervalued.
Key valuation signals for NSE:MADHAVBAUG:
Pretax Margin %: 7.62% (65% above median its 10-year median of 4.62)
GF Value™: ₹228.11 vs. price of ₹177.00 (22.4% below fair value)
Industry Position: 4.6% above the Drug Manufacturers median (#393 of 956)
No single metric tells the full story. See the NSE:MADHAVBAUG stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Vaidyane Ayurved Laboratories Business Description
Vaidya Sane Ayurved Laboratories Ltd is a medical service institution. The company engaged in research and development in Ayurvedic Medicines and the sale of Ayurvedic medicines & products through its various franchises and own clinics. The Company is also engaged in providing Ayurved medical professional services across its various clinics, including panchkarma and other Ayurvedic treatments through the running of an Ayurvedic Hospital. The company mainly offers treatment for health disease reversal, diabetes reversal, BP management, obesity management, and knee pain relief. The company's business is divided into three segments, i.e., Hospital Activity, Sale of Product, and Common. It derives maximum revenue from the sale of Products.
82GF Score
Get the complete analysis for NSE:MADHAVBAUG
Pretax Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:MADHAVBAUG has been successfully added to your 
